Andersen-Tawil syndrome medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Overview
There is no treatment for Andersen-Tawil Syndrome; the mainstay of therapy is to treat the symptoms and manage the patient. Potassium levels play an important role in the management of the symptoms.
Medical Therapy
Medical Therapy
Serum potassium management
- Serum potassium plays an important role in managing the symptoms of the patients with Andersen-Tawil Syndrome.
- If serum potassium levels are <3.0 mmol/L treat the patient with the following:
- Preferred regimen (1): Oral potassium 20-30 mEq/L with the intervals of every 15-30 minutes until the patient reaches the normal levels.
- Specific instructions:
- Physicians who are treating the patient have to keep in mind that anywhere not more than 200 mEq in a 12-hour period is considered to prevent the toxicity.
- Preferred regimen (2): If intravenous potassium is considered then a 5% mannitol solution in the place of a saline or glucose solution is recommended
- Specific instructions:
- While giving the potassium to a patient it is very important to monitor very closely as to avoid secondary hyperkalemia which might leads to diastolic arrest.
- If the patient’s potassium levels are high and causes episodic paralysis it will resolve within an hour.
- High potassium levels can be managed by treating the patient with the following:
- Preferred regimen (3): Intravenous calcium gluconate
Cardiac manifestations
- Cardiac manifestations like ventricular arrhythmias occurs in patients with Andersen-Tawil Syndrome treat the patient with the following:[1][2]
Flecainide
- Flecainide should be considered especially in patients who are prone to more frequent ventricular arrhythmias with reduced left ventricular function
- Flecainide is very potent anti arrhythmic which helps with suppressing bidirectional ventricular tachycardia (BVT)[3]
- Flecainide also helps in reversing tachycardia-induced cardiomyopathy
- Preferred regimen (1): Flecainide 50 mg PO BID, may increase by 50 mg but do not exceed 300 mg/day.
References
References
- ↑ Bökenkamp, Regina; Wilde, Arthur A.; Schalij, Martin J.; Blom, Nico A. (2007). “Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome”. Heart Rhythm. 4 (4): 508–511. doi:10.1016/j.hrthm.2006.12.031. ISSN 1547-5271.
- ↑ Fox DJ, Klein GJ, Hahn A, Skanes AC, Gula LJ, Yee RK; et al. (2008). “Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome”. Europace. 10 (8): 1006–8. doi:10.1093/europace/eun180. PMID 18621769.
- ↑ Pellizzón OA, Kalaizich L, Ptácek LJ, Tristani-Firouzi M, Gonzalez MD (2008). “Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome”. J Cardiovasc Electrophysiol. 19 (1): 95–7. doi:10.1111/j.1540-8167.2007.00910.x. PMID 17655675.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
